GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Cepheid (NAS:CPHD) » Definitions » EPS without NRI

Cepheid (Cepheid) EPS without NRI : $-0.51 (TTM As of Sep. 2016)


View and export this data going back to 2000. Start your Free Trial

What is Cepheid EPS without NRI?

Cepheid's earnings per share without non-recurring items for the three months ended in Sep. 2016 was $-0.15. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2016 was $-0.51.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cepheid's EPS without NRI or its related term are showing as below:

CPHD's 3-Year EPS without NRI Growth Rate is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.7
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Cepheid's EPS (Diluted) for the three months ended in Sep. 2016 was $-0.15. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2016 was $-0.51.

Cepheid's EPS (Basic) for the three months ended in Sep. 2016 was $-0.15. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2016 was $-0.51.


Cepheid EPS without NRI Historical Data

The historical data trend for Cepheid's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cepheid EPS without NRI Chart

Cepheid Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 -0.30 -0.27 -0.72 -0.67

Cepheid Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.32 -0.13 -0.09 -0.14 -0.15

Competitive Comparison of Cepheid's EPS without NRI

For the Diagnostics & Research subindustry, Cepheid's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cepheid's PE Ratio without NRI Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cepheid's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cepheid's PE Ratio without NRI falls into.



Cepheid EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cepheid  (NAS:CPHD) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cepheid EPS without NRI Related Terms

Thank you for viewing the detailed overview of Cepheid's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Cepheid (Cepheid) Business Description

Traded in Other Exchanges
N/A
Address
Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.
Executives
Thomas D Brown director 28161 N. KEITH DRIVE, LAKE FOREST IL 60045
Steele Glenn Jr Md Phd director 250 TECHNOLOGY PARK, LAKE MARY FL 32746-6232
Hollings Renton director
John L Bishop director, officer: Chairman of the Board and CEO
Marc Haugen officer: EVP, Global Ops & Engineering C/O CEPHEID, 904 CARIBBEAN DRIVE, SUNNYVALE CA 94089
Ilan Daskal officer: EVP, Chief Financial Officer 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Andrew Miller officer: EVP, CFO 111 MCINNIS PARKWAY, SAN RAFAEL CA 94903
Jim Post officer: EVP, NA Commercial Operations 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453

Cepheid (Cepheid) Headlines

From GuruFocus

CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares

By GuruFocus Research GuruFocus Editor 02-28-2011

CEPHEID Reports Operating Results (10-Q)

By gurufocus 05-07-2009

CEPHEID Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2009

CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares

By GuruFocus Research GuruFocus Editor 02-08-2011

CEPHEID Reports Operating Results (10-Q)

By gurufocus 10qk 08-04-2010

CEPHEID Reports Operating Results (10-Q)

By gurufocus 10qk 05-04-2010

CEPHEID Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2010

Baron Funds Comments on Cepheid

By Holly LaFon Holly LaFon 02-08-2016

CEPHEID (CPHD) SVP, CFO Andrew Miller sells 2,500 Shares

By GuruFocus Research GuruFocus Editor 02-15-2011

CEPHEID (CPHD) SVP, CFO Andrew Miller sells 10,000 Shares

By GuruFocus Research GuruFocus Editor 12-10-2010